Tharimmune, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
THAR Nasdaq 2830 www.tharimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tharimmune, Inc.

Crypto treasury companies pivot to fringe tokens, stoking volatility fears - Nov 10th, 2025 4:02 am
Tharimmune Stock Gains 30%, on $540M Capital Raise to Build Canton Coin Treasury Strategy - Nov 3rd, 2025 7:54 am
Pleasing Signs As A Number Of Insiders Buy Tharimmune Stock - Sep 30th, 2025 4:24 am
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl - Sep 4th, 2025 6:01 am
Tharimmune (THUR) Tumbles 20.7% on $5-Million Share Sale - Aug 27th, 2025 10:02 am
BC-Most Active Stocks - Aug 25th, 2025 8:30 am
Sector Update: Health Care Stocks Advance Late Afternoon - Aug 20th, 2025 1:56 pm
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments - Aug 20th, 2025 6:00 am
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl - Aug 13th, 2025 6:01 am
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors - Aug 5th, 2025 6:00 am
Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery - Aug 4th, 2025 6:00 am
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants - Jul 23rd, 2025 8:15 pm
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors - Jun 17th, 2025 6:01 am
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - May 19th, 2025 6:01 am
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback - May 6th, 2025 6:01 am
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences - May 1st, 2025 6:01 am
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors - Apr 30th, 2025 6:01 am
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - Apr 28th, 2025 6:01 am
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - Apr 15th, 2025 7:00 am
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Apr 7th, 2025 6:00 am